At a glance
- Originator Bristol-Myers Squibb
- Class Anti-inflammatories
- Mechanism of Action Selectin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Inflammation
Most Recent Events
- 18 Jan 2005 Discontinued - Preclinical for Inflammation in Canada (unspecified route)
- 18 Jan 2005 Discontinued - Preclinical for Inflammation in USA (unspecified route)
- 05 Mar 1998 Preclinical development for Inflammation in Canada (Unknown route)